格隆汇3月26日丨奥星生命科技(06118.HK)发布公告，截至2024年12月31日止年度，集团录得收入约人民币15.004亿元，较2023年同期减少14.9%，主要由于集团在2023年全年的订单量大幅下降约32.7%，导致期初未完工合同减少。然而，与2023年录得的亏损相比，2024年的税后净利润显示已转亏为盈，2024年的订单承接量与2023年同期相比增加12.1%。该项转亏为盈乃由于管理层坚毅不屈的努力，能够应对中国市场激烈竞争的挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.